The US Has Reclassified Cannabis. Here's What That Actually Means

In April 2026, the United States Department of Justice finalised the reclassification of cannabis from Schedule I to Schedule III under the Controlled Substances Act. It is the most significant shift in federal drug policy in the United States in decades, and it took over 50 years of advocacy, litigation, and science to get there.

Schedule I vs Schedule III

Schedule I classification, where cannabis has sat since 1970, means a substance is deemed to have no accepted medical use and a high potential for abuse. It is the same category as heroin. Schedule III means the substance has accepted medical uses and a lower potential for abuse. The reclassification is a federal acknowledgement — for the first time — that cannabis has legitimate medical value.

In practical terms, this does not federally legalise cannabis. State-by-state recreational legalisation continues on its own track. But the knock-on effects are significant.

What Changes

The most immediately felt change is the removal of the 280E tax provision. Under the old classification, cannabis businesses could not deduct ordinary business expenses from their federal taxes. This applied the full rate of tax to their gross income — a crushing burden that has driven many state-legal businesses into financial difficulty. Schedule III removes that burden.

Research also becomes significantly easier. Schedule I status has historically blocked or complicated medical research into cannabis, creating a bizarre situation where the substance was legal in dozens of states but nearly impossible to study formally at the federal level. That changes.

DEA Hearings and the Science

Extensive DEA-led hearings began in June 2026 to evaluate the scientific and medical evidence underpinning the reclassification. These hearings represent the first time the United States federal government has formally argued in favour of cannabis's medical legitimacy in court — a remarkable turnaround for an institution that spent decades insisting the plant was worthless and dangerous.

For patients, researchers, and the communities who have fought longest and hardest for this shift, the reclassification is real progress. It is not the end of the road. But it is unmistakably a step in the right direction.

Sources: US Department of Justice Rescheduling Order April 2026, DEA Hearings June 2026, NORML, Marijuana Moment.